Selected research
Industry Research
New Drug for Alzheimer's Treatment Industry Research Report 2026
Market perspective
The global New Drug for Alzheimer's Treatment market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for New Drug for Alzheimer's Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for New Drug for Alzheimer's Treatment is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for New Drug for Alzheimer's Treatment is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of New Drug for Alzheimer's Treatment include Simcere, Eisai, Johnson and Johnson, Green Valley, Roche, Eli Lilly, Biogen, AstraZeneca and Vivoryon, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global New Drug for Alzheimer's Treatment market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
New Drug for Alzheimer's Treatment Market by Company
Simcere
Eisai
Johnson and Johnson
Green Valley
Roche
Eli Lilly
Biogen
AstraZeneca
Vivoryon
Neurimmune
New Drug for Alzheimer's Treatment Segment by Type
AChE Target
Aβ Target
BChE Target
Others
New Drug for Alzheimer's Treatment Segment by Application
Mild Cognitive Impairment Stage
Preclinical Stage
Dementia Stage
New Drug for Alzheimer's Treatment Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global New Drug for Alzheimer's Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of New Drug for Alzheimer's Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of New Drug for Alzheimer's Treatment.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of New Drug for Alzheimer's Treatment manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of New Drug for Alzheimer's Treatment by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of New Drug for Alzheimer's Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- AChE Target
- Aβ Target
- BChE Target
- Others
Applications
- Mild Cognitive Impairment Stage
- Preclinical Stage
- Dementia Stage
Companies covered
- Simcere
- Eisai
- Johnson and Johnson
- Green Valley
- Roche
- Eli Lilly
- Biogen
- AstraZeneca
- Vivoryon
- Neurimmune
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global New Drug for Alzheimer's Treatment Market Size (2021-2032)
- 2.2.2 Global New Drug for Alzheimer's Treatment Sales (2021-2032)
- 2.2.3 Global New Drug for Alzheimer's Treatment Market Average Price (2021-2032)
- 2.3 New Drug for Alzheimer's Treatment by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 AChE Target
- 2.3.3 Aβ Target
- 2.3.4 BChE Target
- 2.3.5 Others
- 2.4 New Drug for Alzheimer's Treatment by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Mild Cognitive Impairment Stage
- 2.4.3 Preclinical Stage
- 2.4.4 Dementia Stage
3 Market Competitive Landscape by Manufacturers
- 3.1 Global New Drug for Alzheimer's Treatment Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global New Drug for Alzheimer's Treatment Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global New Drug for Alzheimer's Treatment Revenue of Manufacturers (2021-2026)
- 3.4 Global New Drug for Alzheimer's Treatment Average Price by Manufacturers (2021-2026)
- 3.5 Global New Drug for Alzheimer's Treatment Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of New Drug for Alzheimer's Treatment, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of New Drug for Alzheimer's Treatment, Product Type & Application
- 3.8 Global Manufacturers of New Drug for Alzheimer's Treatment, Established Date
- 3.9 Global New Drug for Alzheimer's Treatment Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Simcere
- 4.1.1 Simcere Company Information
- 4.1.2 Simcere Business Overview
- 4.1.3 Simcere New Drug for Alzheimer's Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Simcere New Drug for Alzheimer's Treatment Product Portfolio
- 4.1.5 Simcere Recent Developments
- 4.2 Eisai
- 4.2.1 Eisai Company Information
- 4.2.2 Eisai Business Overview
- 4.2.3 Eisai New Drug for Alzheimer's Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Eisai New Drug for Alzheimer's Treatment Product Portfolio
- 4.2.5 Eisai Recent Developments
- 4.3 Johnson and Johnson
- 4.3.1 Johnson and Johnson Company Information
- 4.3.2 Johnson and Johnson Business Overview
- 4.3.3 Johnson and Johnson New Drug for Alzheimer's Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Johnson and Johnson New Drug for Alzheimer's Treatment Product Portfolio
- 4.3.5 Johnson and Johnson Recent Developments
- 4.4 Green Valley
- 4.4.1 Green Valley Company Information
- 4.4.2 Green Valley Business Overview
- 4.4.3 Green Valley New Drug for Alzheimer's Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Green Valley New Drug for Alzheimer's Treatment Product Portfolio
- 4.4.5 Green Valley Recent Developments
- 4.5 Roche
- 4.5.1 Roche Company Information
- 4.5.2 Roche Business Overview
- 4.5.3 Roche New Drug for Alzheimer's Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Roche New Drug for Alzheimer's Treatment Product Portfolio
- 4.5.5 Roche Recent Developments
- 4.6 Eli Lilly
- 4.6.1 Eli Lilly Company Information
- 4.6.2 Eli Lilly Business Overview
- 4.6.3 Eli Lilly New Drug for Alzheimer's Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Eli Lilly New Drug for Alzheimer's Treatment Product Portfolio
- 4.6.5 Eli Lilly Recent Developments
- 4.7 Biogen
- 4.7.1 Biogen Company Information
- 4.7.2 Biogen Business Overview
- 4.7.3 Biogen New Drug for Alzheimer's Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Biogen New Drug for Alzheimer's Treatment Product Portfolio
- 4.7.5 Biogen Recent Developments
- 4.8 AstraZeneca
- 4.8.1 AstraZeneca Company Information
- 4.8.2 AstraZeneca Business Overview
- 4.8.3 AstraZeneca New Drug for Alzheimer's Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 AstraZeneca New Drug for Alzheimer's Treatment Product Portfolio
- 4.8.5 AstraZeneca Recent Developments
- 4.9 Vivoryon
- 4.9.1 Vivoryon Company Information
- 4.9.2 Vivoryon Business Overview
- 4.9.3 Vivoryon New Drug for Alzheimer's Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Vivoryon New Drug for Alzheimer's Treatment Product Portfolio
- 4.9.5 Vivoryon Recent Developments
- 4.10 Neurimmune
- 4.10.1 Neurimmune Company Information
- 4.10.2 Neurimmune Business Overview
- 4.10.3 Neurimmune New Drug for Alzheimer's Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Neurimmune New Drug for Alzheimer's Treatment Product Portfolio
- 4.10.5 Neurimmune Recent Developments
5 Global New Drug for Alzheimer's Treatment Market Scenario by Region
- 5.1 Global New Drug for Alzheimer's Treatment Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global New Drug for Alzheimer's Treatment Sales by Region: 2021-2032
- 5.2.1 Global New Drug for Alzheimer's Treatment Sales by Region: 2021-2026
- 5.2.2 Global New Drug for Alzheimer's Treatment Sales by Region: 2027-2032
- 5.3 Global New Drug for Alzheimer's Treatment Revenue by Region: 2021-2032
- 5.3.1 Global New Drug for Alzheimer's Treatment Revenue by Region: 2021-2026
- 5.3.2 Global New Drug for Alzheimer's Treatment Revenue by Region: 2027-2032
- 5.4 North America New Drug for Alzheimer's Treatment Market Facts & Figures by Country
- 5.4.1 North America New Drug for Alzheimer's Treatment Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America New Drug for Alzheimer's Treatment Sales by Country (2021-2032)
- 5.4.3 North America New Drug for Alzheimer's Treatment Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe New Drug for Alzheimer's Treatment Market Facts & Figures by Country
- 5.5.1 Europe New Drug for Alzheimer's Treatment Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe New Drug for Alzheimer's Treatment Sales by Country (2021-2032)
- 5.5.3 Europe New Drug for Alzheimer's Treatment Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific New Drug for Alzheimer's Treatment Market Facts & Figures by Country
- 5.6.1 Asia Pacific New Drug for Alzheimer's Treatment Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific New Drug for Alzheimer's Treatment Sales by Country (2021-2032)
- 5.6.3 Asia Pacific New Drug for Alzheimer's Treatment Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America New Drug for Alzheimer's Treatment Market Facts & Figures by Country
- 5.7.1 South America New Drug for Alzheimer's Treatment Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America New Drug for Alzheimer's Treatment Sales by Country (2021-2032)
- 5.7.3 South America New Drug for Alzheimer's Treatment Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa New Drug for Alzheimer's Treatment Market Facts & Figures by Country
- 5.8.1 Middle East and Africa New Drug for Alzheimer's Treatment Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa New Drug for Alzheimer's Treatment Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa New Drug for Alzheimer's Treatment Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global New Drug for Alzheimer's Treatment Sales by Type (2021-2032)
- 6.1.1 Global New Drug for Alzheimer's Treatment Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global New Drug for Alzheimer's Treatment Sales Market Share by Type (2021-2032)
- 6.2 Global New Drug for Alzheimer's Treatment Revenue by Type (2021-2032)
- 6.2.1 Global New Drug for Alzheimer's Treatment Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global New Drug for Alzheimer's Treatment Revenue Market Share by Type (2021-2032)
- 6.3 Global New Drug for Alzheimer's Treatment Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global New Drug for Alzheimer's Treatment Sales by Application (2021-2032)
- 7.1.1 Global New Drug for Alzheimer's Treatment Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global New Drug for Alzheimer's Treatment Sales Market Share by Application (2021-2032)
- 7.2 Global New Drug for Alzheimer's Treatment Revenue by Application (2021-2032)
- 7.2.1 Global New Drug for Alzheimer's Treatment Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global New Drug for Alzheimer's Treatment Revenue Market Share by Application (2021-2032)
- 7.3 Global New Drug for Alzheimer's Treatment Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 New Drug for Alzheimer's Treatment Value Chain Analysis
- 8.1.1 New Drug for Alzheimer's Treatment Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 New Drug for Alzheimer's Treatment Production Mode & Process
- 8.2 New Drug for Alzheimer's Treatment Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 New Drug for Alzheimer's Treatment Distributors
- 8.2.3 New Drug for Alzheimer's Treatment Customers
9 Global New Drug for Alzheimer's Treatment Analyzing Market Dynamics
- 9.1 New Drug for Alzheimer's Treatment Industry Trends
- 9.2 New Drug for Alzheimer's Treatment Industry Drivers
- 9.3 New Drug for Alzheimer's Treatment Industry Opportunities and Challenges
- 9.4 New Drug for Alzheimer's Treatment Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst